Skip to main content
. 2016 Sep 25;22(3):339–349. doi: 10.3350/cmh.2016.0021

Figure 3.

Figure 3.

Differences in virological response at 96 weeks (A), biochemical response at 96 weeks (B), and HBeAg seroconversion (C) in CHB patients treated with entecavir. BMI, body mass index; WHR, waist-hip-ratio; VFA, visceral fat area; CHB, chronic hepatitis B; HBeAg, hepatitis B virus envelope antigen. *Statistical significance is regarded when P-value is less than 0.05.